to treat bladder cancer. The development comes in response to significant supply shortages of Tice BCG [an attenuated, live ...

ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...

a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have created a significant ...

Supply shortages of TICE BCG in the U.S. have become a significant impediment to the treatment of bladder cancer patients. In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated ...

Following surgery to remove the tumor, bladder cancer patients are typically given a live Bacillus Calmette Guerin (BCG) ...

ImmunityBio markets Anktiva, a "novel IL-15 receptor superagonist complex," with BCG for the treatment of “adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma ...

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S. Supply shortages of TICE ® BCG in the U.S. have become a significant ...

[JONAH ONYANGO/STANDARD.] A nationwide shortage of Bacillus Calmette-Guerin (BCG) vaccines in the country leaves Kenyan newborns vulnerable to Tuberculosis (TB), a disease with a high prevalence ...

that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S. Supply shortages of TICE® BCG in the U.S. have become a significant ...